Critical Care Diagnostics Market: as CMS ties Hospital Value-Based Purchasing payment to SEP-1 sepsis bundle compliance, ICU and emergency department diagnostic turnaround time converts from a clinical quality metric into a direct hospital reimbursement lever, so point-of-care high-sensitivity troponin and sepsis detection platforms move from a nice-to-have workflow improvement to a payment-linked infrastructure requirement, and vendors that can prove measurable SEP-1 bundle compliance improvement capture the resulting capital budget priority.

The global critical care diagnostics market size was USD 7.62 Billion in 2025 and is expected to register a revenue CAGR of 7.4% during the forecast period. Market revenue growth is driven by factors such as CMS inclusion of the SEP-1 sepsis bundle in Hospital Value-Based Purchasing, FDA clearance momentum for validated point-of-care high-sensitivity troponin assays, and the emergence of novel host-response diagnostics that detect sepsis through immune cell behaviour rather than pathogen identification alone. The first driving factor is CMS’s inclusion of SEP-1 sepsis bundle compliance as a measure within Hospital Value-Based Purchasing, which ties hospital Medicare payment directly to the speed and completeness of sepsis care delivery. This payment linkage gives hospitals a direct financial incentive to invest in diagnostic infrastructure that accelerates sepsis recognition and treatment initiation, not merely a clinical quality rationale. The second driving factor is FDA clearance momentum for point-of-care high-sensitivity cardiac troponin assays that bring laboratory-grade sensitivity to the bedside. Abbott received FDA clearance in January 2025 for its i-STAT high-sensitivity troponin I assay, and QuidelOrtho received clearance in November 2025 for its VITROS high-sensitivity Troponin I Assay, both extending high-sensitivity cardiac biomarker testing beyond centralized laboratory settings. The third driving factor is the emergence of novel host-response diagnostics, such as Cytovale’s IntelliSep, that detect sepsis through biophysical changes in immune cells rather than relying solely on pathogen identification or inflammatory biomarker levels. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way SEP-1 bundle compliance infrastructure widens its own value as more hospital departments coordinate around the same rapid-diagnosis workflow, letting each new point-of-care platform placement improve bundle compliance metrics across emergency department, ICU, and general ward sepsis presentations simultaneously. Once a hospital builds SEP-1-compliant rapid diagnostic workflows in its emergency department, extending that same workflow to inpatient units where sepsis can also originate compounds the value of the initial investment without requiring a fully separate diagnostic infrastructure build, so the value of SEP-1 compliance investment grows as it spreads across a hospital’s care settings. As a result, demand and revenue share are concentrating around diagnostic platforms that demonstrably improve SEP-1 bundle compliance and Hospital Value-Based Purchasing scores, and the forecast tilts toward vendors that can produce hospital-level outcomes evidence rather than analytical performance data alone. For instance, in 2025, Cytovale, United States, reported accelerating hospital system adoption of its FDA-cleared IntelliSep rapid sepsis detection test, raising USD 100 million in Series D financing to expand commercial deployment as health systems sought measurable improvement in emergency department sepsis recognition speed. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is CMS’s inclusion of SEP-1 sepsis bundle compliance as a scored measure within Hospital Value-Based Purchasing, directly linking Medicare payment to sepsis care speed and completeness. SEP-1 bundle compliance requires completing multiple time-sensitive diagnostic and treatment steps within defined windows, and this requirement works only if a hospital has diagnostic infrastructure fast enough to support it, so payment policy and point-of-care diagnostic investment reinforce each other directly. Hospitals scored on SEP-1 bundle compliance under Hospital Value-Based Purchasing face direct Medicare payment consequences for slow or incomplete sepsis care, creating a financial incentive for diagnostic infrastructure investment that goes beyond clinical quality improvement alone. The recent record shows the pace. Cytovale reported accelerating hospital system adoption of its FDA-cleared IntelliSep sepsis detection test through 2025, raising USD 100 million in Series D financing specifically to expand commercial deployment in response to hospital demand for SEP-1-supporting diagnostic tools. The effect on the market is that sepsis diagnostic infrastructure investment decisions are increasingly made by hospital finance and quality leadership alongside clinical leadership, reflecting the direct reimbursement stakes. These are some of the key factors driving revenue growth of the market.

The second driver is the FDA clearance of point-of-care high-sensitivity troponin assays that match the analytical sensitivity of central laboratory testing without the turnaround time delay. Point-of-care high-sensitivity troponin testing works only if the assay achieves the sensitivity threshold defined by international cardiac biomarker guidelines, and clearing that bar is what has taken point-of-care troponin from a screening tool to a guideline-concordant diagnostic in its own right, so assay sensitivity improvement and clinical adoption expansion move together. Abbott received FDA clearance in January 2025 for its i-STAT high-sensitivity troponin I assay, and QuidelOrtho received clearance in November 2025 for its VITROS high-sensitivity Troponin I Assay, both extending high-sensitivity cardiac biomarker testing beyond centralized laboratory settings into point-of-care and near-patient formats. The effect on the market is that emergency departments can now rule out myocardial infarction using point-of-care testing alone in an accelerated timeframe, reducing dependence on central laboratory turnaround time for a high-volume clinical decision. These are some of the key factors driving revenue growth of the market.

“Cytovale’s IntelliSep test, cleared by the FDA to aid early sepsis detection, delivers a risk stratification result in about eight minutes by analysing the biomechanical properties of white blood cells rather than measuring pathogen presence or a single inflammatory biomarker.”

The third driver is the emergence of host-response diagnostics that assess the body’s immune activation state rather than relying solely on identifying a specific pathogen or measuring a single inflammatory biomarker. Traditional sepsis biomarkers such as procalcitonin and lactate provide useful but incomplete signals, and host-response diagnostics work by directly measuring immune cell biophysical changes that occur early in the septic response, so this technology addresses a genuine gap in the existing sepsis diagnostic toolkit rather than simply replicating an existing test faster. Cytovale’s IntelliSep test analyses the biomechanical properties of white blood cells using microfluidics and high-speed imaging, delivering a sepsis risk stratification result in about eight minutes from a standard blood draw, and multiple health systems adopted the platform across their emergency departments during 2025. The effect on the market is that sepsis diagnostics is expanding from a single-biomarker paradigm toward a multi-modal toolkit combining pathogen detection, inflammatory biomarkers, and host-response assessment. These are some of the key factors driving revenue growth of the market.

However, the critical care diagnostics market faces severe adoption constraints from persistent under-utilisation of high-sensitivity cardiac assays at US hospitals, SEP-1 sepsis bundle measurement complexity, and competition for limited hospital capital budgets. Because many US hospitals have not yet transitioned from conventional to high-sensitivity troponin assays despite FDA clearance and international cardiac biomarker guideline endorsement, a meaningful share of the addressable point-of-care cardiac diagnostics market remains untapped even where the clinical and reimbursement case for adoption is well established, reflecting the practical friction of changing an established emergency department diagnostic workflow. SEP-1 measurement complexity is a second constraint, because the bundle requires coordinated, time-stamped completion of multiple diagnostic and treatment interventions across emergency department, laboratory, and inpatient teams, and imperfect documentation, workflow handoffs, or interpretation ambiguity can cause a hospital to be scored as non-compliant even when clinical care was appropriate, complicating the return-on-investment case that hospital finance leadership requires before approving new diagnostic infrastructure spending. Capital budget competition is the third constraint, since critical care diagnostic platforms compete against many other pressing hospital capital priorities, including facility infrastructure, other clinical service line investments, and general technology modernisation, so demonstrating a clear, quantified reimbursement or outcomes return remains necessary to win budget allocation, and vendors without published hospital-level outcomes evidence face a harder capital approval path. These factors substantially limit critical care diagnostics market growth over the forecast period.

Based on test type, the global critical care diagnostics market is segmented into cardiac biomarker testing, sepsis and infection biomarker testing, and blood gas and electrolyte testing. Cardiac biomarker testing holds the largest revenue share, because chest pain and suspected myocardial infarction represent one of the highest-volume emergency department presentations globally, which suits the growing point-of-care high-sensitivity troponin assay menu from Abbott and QuidelOrtho. Blood gas and electrolyte testing remains established as a foundational ICU monitoring category, and it is a lower-cost, higher-frequency test relative to specialised biomarker panels, but it cannot match the growth trajectory of newer sepsis and cardiac biomarker categories. Sepsis and infection biomarker testing is expected to register the fastest revenue growth rate in the global critical care diagnostics market over the forecast period, driven directly by CMS SEP-1 Hospital Value-Based Purchasing requirements, which is why hospital systems are prioritising rapid sepsis diagnostic infrastructure investment.

Point-of-care immunoassay technology is expected to account for the largest revenue share in the global critical care diagnostics market during the forecast period

Based on technology, the global critical care diagnostics market is segmented into point-of-care immunoassay, molecular/PCR-based testing, and host-response cellular diagnostics. Point-of-care immunoassay holds the largest revenue share, because it underpins the majority of cardiac biomarker and traditional sepsis biomarker testing platforms currently deployed across emergency departments, which suits the established point-of-care instrument installed base. Host-response cellular diagnostics is expected to register the fastest revenue growth rate in the global critical care diagnostics market over the forecast period, driven by Cytovale’s IntelliSep platform expansion and growing hospital recognition of the diagnostic gap traditional biomarkers leave unaddressed, which is why multiple health systems adopted host-response testing during 2025.

Based on application, the global critical care diagnostics market is segmented into emergency department triage, intensive care unit monitoring, and sepsis bundle compliance applications. Emergency department triage holds the largest revenue share, reflecting the highest-volume point-of-care testing setting in acute care hospitals, which suits the concentration of cardiac and sepsis biomarker testing at the point of first patient contact. Sepsis bundle compliance is expected to register rapid revenue growth in the global critical care diagnostics market over the forecast period, driven directly by the CMS Hospital Value-Based Purchasing payment linkage, which is why hospital quality and finance leadership are increasingly co-sponsoring critical care diagnostics capital investment decisions.

Based on regional analysis, the critical care diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because it is the sole jurisdiction where CMS Hospital Value-Based Purchasing directly ties Medicare payment to SEP-1 sepsis bundle compliance, and because Abbott, QuidelOrtho, and Cytovale, leading global critical care diagnostics vendors, concentrate their commercial and regulatory activity in the country. Abbott’s January 2025 i-STAT high-sensitivity troponin clearance and Cytovale’s 2025 IntelliSep commercial expansion both launched first into the United States hospital market. The concentration of SEP-1 reimbursement policy in the United States also means new critical care diagnostic platforms are typically adopted in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national critical care diagnostics markets within Europe. National health system sepsis and cardiac care quality initiatives across the region sustain steady demand, though none carry the direct hospital-level payment linkage that CMS Hospital Value-Based Purchasing creates in the United States. The result is steady rather than rapid growth, shaped more by clinical quality improvement programmes than by a direct reimbursement lever.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and India represent the three largest national critical care diagnostics markets within the region. Expanding hospital intensive care capacity and rising emergency department volumes in China and India are driving new point-of-care diagnostic infrastructure investment from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national critical care diagnostics markets within the region. Private hospital networks in both countries are expanding point-of-care cardiac and sepsis testing capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised point-of-care instruments and cartridges that Latin American hospitals depend on through 2026, slowing adoption beyond the region’s main urban hospital networks.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial critical care diagnostics markets within the GCC. The UAE is the most established critical care diagnostics market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building intensive care and emergency department diagnostic capacity from scratch.